Search results for "Daewoong Pharmaceutical"

Daewoong Pharmaceutical Enters Digital Therapeutics Market with Exclusive Deal for MCI Device 'Cogthera'

Daewoong Pharmaceutical Enters Digital Therapeutics Market with Exclusive Deal for MCI Device 'Cogthera'

Daewoong Pharmaceutical announced on the 22nd that it has signed an exclusive domestic sales and commercialization agreement with digital healthcare...
Daewoong Pharmaceutical Nears Completion of Phase 2 IPF Trial for Bersiporosin, Readout Set for H1 2027

Daewoong Pharmaceutical Nears Completion of Phase 2 IPF Trial for Bersiporosin, Readout Set for H1 2027

Daewoong Pharmaceutical has completed patient enrollment for the global Phase 2 clinical trial of bersiporosin (DWN12088), its first-in-class...
Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2

Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2

South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter,...
Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s botulinum toxin product Nabota has entered Kuwait, expanding its Middle East footprint to...
Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.

Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.

Daewoong Pharmaceutical announced on July 23 that it has severed supply transactions with a domestic medical...
Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch

Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch

Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion...
Daewoong’s Enblo Demonstrates Strong Potential to Reverse Fatty Liver in Diabetes Patients

Daewoong’s Enblo Demonstrates Strong Potential to Reverse Fatty Liver in Diabetes Patients

Daewoong Pharmaceutical announced that its newly developed type 2 diabetes medication, Enblo (active ingredient:...
Daewoong Pharmaceutical Secures 145.2 Billion Won MENA Export Deal for Diabetes Drug Enblo

Daewoong Pharmaceutical Secures 145.2 Billion Won MENA Export Deal for Diabetes Drug Enblo

Daewoong Pharmaceutical’s proprietary type 2 diabetes treatment, Enblo (active ingredient: enavogliflozin), is set to...
Mexico Greenlights Daewoong’s Envlo, Fueling Latin American Expansion

Mexico Greenlights Daewoong’s Envlo, Fueling Latin American Expansion

Daewoong Pharmaceutical announced on May 27 that its type 2 diabetes treatment, Envlo 0.
Daewoong Pharmaceutical Acquires U.S. Cellular Reprogramming Tech to Fast-Track Anti-Aging Therapeutics

Daewoong Pharmaceutical Acquires U.S. Cellular Reprogramming Tech to Fast-Track Anti-Aging Therapeutics

Daewoong Pharmaceutical is accelerating its research and development into anti-aging therapeutics.